Jun Lu Department of Genetics, Yale University School of Medicine, USA
1 protocol

Wen Pan State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
2 protocols
Jia Li SRI International
45 protocols

Jijun Cheng
  • VP, R&D, Shanghai LIDE Biotech
Research focus
  • Cancer biology
  • drug discovery, patient-derived xenograft, genome editing
  • 1 Author merit


Ph.D, University of Kentucky, 1999

Lab information

Cheng Lab


1. Wen Pan, Shu Zhu, Kun Qu, Katrina Meeth, Jijun Cheng, Zheng Wei, Jun Zhao3, Christine Roden, Jun Liu, Bo Guo, Marcus Bosenberg, Richard A.Flavell, Jun Lu. Tet2 Sustains the Immunosuppressive Function of Myeloid Cells and Promotes Melanoma Growth. 2017. Immunity 47, 284–297.
2. Jijun Cheng, Wen Pan and Jun Lu. Dense sgRNA Library Construction Using Molecular Chipper. 2017. Bio-protocols. Vol 7, Iss 12, Jun 20, 2017 DOI:10.21769/BioProtoc.2373.
3. Nayi Wang, Jijun Cheng, Rong Fan, & Jun Lu. Capture, Amplification, and Global Profiling of microRNAs from Low Quantities of Whole Cell Lysate. Catalyst. 2017. 142, 3203-3211.
4. Jun Liu, Bo Guo, Zhuo Chen, Nayi Wang, Michelina Iacovino, Jijun Cheng, Christine Roden, Wen Pan, Sajid Khan, Suning Chen, Michael Kyba, Rong Fan, Shangqin Guo, and Jun Lu. miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism. Blood .2017 Jan 4. doi: 10.1182/blood-2016-06-721027.
5. Christine Roden, Jonathan Gaillard, Shaveta Kanoria, William Rennie, Syndi Barish, Jijun Cheng, Wen Pan, Jun Liu, Chris Cotsapas, Ye Ding and Jun Lu. Novel Determinants of Mammalian Primary microRNA Processing Revealed by Systematic Evaluation of Hairpin-containing Transcripts and Human Genetic Variations. Genome Research. 2017 Jan 13. pii: gr.208900.116. doi: 10.1101/gr.208900.116.
6. Zhiwei Hu, Jie Xu, Jijun Cheng, Elizabeth McMichael, Lianbo Yu, and William E. 2016. Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. Oncotarget. Jan 3;8(1):1481-1494. doi: 10.18632/oncotarget.13644. (Icon Immuno-therapy)
8. Z Hu, J Cheng, J Xu, W Ruf, CJ Lockwood. 2016. Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy. Angiogenesis. doi:10.1007/s10456-016-9530-9.
9. Cheng J *, Pan W, Roden C, Chen Z, Lu J (2016) Molecular Chipper: Functional Mapping of the Non-Coding Genome with CRISPR. Next Generat Sequenc & Applic 3:132. doi:10.4172/2469-9853.1000132 (* corresponding author)
10. Eriona Hysolli, Yoshiaki Tanaka, Juan Su, Kun-Yong Kim, Tianyu Zhong, Ralf Janknecht, Xiao-Ling Zhou, Lin Geng, Caihong Qiu, Xinghua Pan, Yong-Wook Jung, Jijun Cheng, Jun Lu, Mei Zhong, Sherman M Weissman, In-Hyun Park. 2016. Regulation of the DNA Methylation Landscape in Human Somatic Cell Reprogramming by the miR-29 Family. Stem Cell Reports 7(1):43–54.
11. Jijun Cheng (* co-corresponding author), Christine A. Roden, Wen Pan, Shu Zhu, Xinghua Pan, Tingting Jiang, Yuval Kluger, Sherman M. Weissman, Richard A. Flavell, Ye Ding and Jun Lu. 2015. A Molecular Chipper Technology for CRISPR sgRNA Library Generation and Functional Mapping of Noncoding Regions. Nature Communications. 2016 Mar 30;7:11178. doi: 10.1038/ncomms11178.
12. Yaozu Xiang, Jijun Cheng, Gourg Atteya, Yi Xie, Jeremiah Stitham, Jing Du, Geralyn Spollett, Jun Lu, Kathleen Martin, John Hwa. 2015. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of Von Willebrand Factor. Blood 125(22):3377-87.
13. Ping-xia Zhang, Jijun Cheng, Jun Lu, John L. Koff, Siying Zou, Anthony D'Souza, Patty J. Lee, Diane S. Krause, Marie E. Egan and Emanuela M. Bruscia. 2015. Pharmacological down-regulation of microRNA199-5p ameliorates cystic fibrosis lung hyper-inflammation. Nature Communications. 6:6221.
14. Ding, Ye; Liu, Chaochun; Rennie, William; Carmack, C. Steven; Kanoria, Shaveta; Cheng, Jijun; Lu, Jun. 2014. Effects of genetic variations on microRNA:target interactions. Nucleic Acid Research. 42 (15): 9543-9552.
15. S. Guo, X. Zi, V. Schulz, J. Cheng, M. Zhong, S. H.J. Koochaki, C. M. Megyola, X. Pan, K. Heydari, Sh. M. Weissman, P. G. Gallagher, D. S. Krause, R. Fan, and J. Lu. 2014. Non-stochastic reprogramming from a privileged somatic cell state. CELL. 156, 1–14.
16. Cheng J, Guo S, Chen S, Mastriano SJ, Liu C, D'Alessio AC, Hysolli E, Guo Y, Yao H, Megyola CM, Li D, Liu J, Pan W, Roden CA, Zhou XL, Heydari K, Chen J, Park IH, Ding Y, Zhang Y, Lu J. 2013. An Extensive Network of TET2-Targeting microRNAs as a New Mechanism of Hematopoietic Malignancy. Cell Reports. 5(2):471-81.
17. Megyola CM, Gao Y, Teixeira AM, Cheng J, Heydari K, Cheng EC, Nottoli T, Krause DS, Lu J, Guo S. 2013. Dynamic Migration and Cell-Cell Interactions of Early Reprogramming Revealed by High Resolution Time-lapse Imaging. Stem Cells. 31(5):895-905.
18. Adams BD, Guo S, Bai H, Guo Y, Megyola CM, Cheng J, Heydari K, Xiao C, Reddy EP, Lu J. 2012. An In Vivo Functional Screen Uncovers miR-150-Mediated Inhibition of Hematopoietic Recovery. Cell Reports. 2(4):1048-60.
19. J. Cheng, J. Xu, J. Duanmu, H. Zhou, C. J. Booth and Z. Hu. 2012. Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy. Current Cancer Drug Targets. 11(9):1069-1081.
20. Duanmu J, Cheng J, Xu J, Booth CJ, Hu Z. 2011. Effective treatment of chemo-resistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. Br J Cancer. 104(9):1401-9.
21. Agarwal A, Louise-May S, Thanassi JA, Podos SD, Cheng J, Thoma C, Liu C, Wiles JA, Nelson DM, Phadke AS, Bradbury BJ, Deshpande MS, Pucci MJ. 2007. Small molecule inhibitors of E. coli primase, a novel bacterial target. Bioorg Med Chem Lett. 17(10):2807-10.
22. Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ. 2007. Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2445-2453.
23. Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA Jr, Bradbury BJ, Deshpande M. 2007. In Vitro and In Vivo Antibacterial Activities of Isothiazoloquinolones (ITQs) Against Resistant Gram-Positive Pathogens. Antimicrob. Agents Chemother. 51(4):1259-67.
24. Wang Q, Lucien E, Hashimoto A, Pais GC, Nelson DM, Song Y, Thanassi JA, Marlor CW, Thoma CL, Cheng J, Podos SD, Ou Y, Deshpande M, Pucci MJ, Buechter DD, Bradbury BJ, Wiles JA. 2007. Isothiazoloquinolones with Enhanced Anti-staphylococcal Activities against Multi-Drug-Resistant Strains: Effects of Structural Modifications at the 6-, 7-, and 8-Positions. J. Med Chem. 50:199-210.
25. Wiles JA, Song Y, Wang Q, Lucien E, Hashimoto A, Cheng J, Marlor CW, Ou Y, Podos SD, Thanassi JA, Thoma CL, Deshpande M, Pucci MJ, Bradbury BJ. 2006. Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett. 16(5):1277-1281.
26. Wiles JA, Wang Q, Lucien E, Hashimoto A, Song Y, Cheng J, Marlor CW, Ou Y, Podos SD, Thanassi JA, Thoma CL, Deshpande M, Pucci MJ, Bradbury BJ. 2006. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: Synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorg Med Chem Lett. 16(5):1272-1276.
27. Wiles JA, Hashimoto A, Thanassi JA, Cheng J, Incarvito CD, Deshpande M, Pucci MJ, Bradbury BJ. 2006. Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J Med Chem. 49(1):39-42.
28. Cheng J, Park TS, Chio LC, Fischl AS, Ye XS. 2003. Induction of apoptosis by sphingoid long-chain bases in Aspergillus nidulans. Mol. Cell. Biol. 23 (1), 163-177.
29. Cheng J, Park TS, Fischl AS, Ye XS. 2001. Cell cycle progression and cell polarity require sphingolipid biosynthesis in Aspergillus nidulans. Mol. Cell. Biol. 21 (18), 6198-209.
30. Lies CM, Cheng J, James SW, Morris NR, O'Connell MJ, Mirabito PM. 1998. BIMAAPC3, a component of the Aspergillus anaphase promoting complex/cyclosome, is required for a G2 checkpoint blocking entry into mitosis in the absence of NIMA function. J. Cell Sci. 111, 1453-1465.
31. Shugang Dong, Chengqiu Fu, Jijun Cheng and Mingjun Gao. 2000. Genetic control by allozymes in Artemia. Periodical of Ocean University of China. 02 :102-108.
32. Mingjun Gao, Jijun Cheng and Yaneng Cai. 1995. Functional study on rare males in parthenogenesis Artemia. Chinese Science Bulletin. 15: 2276-2781.

1 Protocol published
Dense sgRNA Library Construction Using a Molecular Chipper Approach
Authors:  Jijun Cheng, Wen Pan and Jun Lu, date: 06/20/2017, view: 2703, Q&A: 0
Genetic screens using single-guide-RNA (sgRNA) libraries and CRISPR technology have been powerful to identify genetic regulators for both coding and noncoding regions of the genome. Interrogating functional elements in noncoding regions requires ...
1 Protocol reviewed
Isolation of LYVE-1+ Endothelial Cells from Mouse Embryos
Author:  Patrick Crosswhite, date: 08/05/2018, view: 114, Q&A: 0
Lymphatic vessel endothelial hyaluronan receptor 1, or LYVE-1, is a type 1 integral membrane glycoprotein expressed by lymphatic endothelial cells (LECs). LYVE-1 is commonly used as a biological marker to visually distinguish developing lymphatic ...
More >